212 related articles for article (PubMed ID: 19034038)
21. Comparative pharmacology of guinea pig cardiac myocyte and cloned hERG (I(Kr)) channel.
Davie C; Pierre-Valentin J; Pollard C; Standen N; Mitcheson J; Alexander P; Thong B
J Cardiovasc Electrophysiol; 2004 Nov; 15(11):1302-9. PubMed ID: 15574182
[TBL] [Abstract][Full Text] [Related]
22. HERG K+ channel blockade by the novel antiviral drug sophocarpine.
Zhao XL; Qi ZP; Fang C; Chen MH; Lv YJ; Li BX; Yang BF
Biol Pharm Bull; 2008 Apr; 31(4):627-32. PubMed ID: 18379053
[TBL] [Abstract][Full Text] [Related]
23. Prolongation of cardiac ventricular repolarization under paliperidone: how and how much?
Vigneault P; Kaddar N; Bourgault S; Caillier B; Pilote S; Patoine D; Simard C; Drolet B
J Cardiovasc Pharmacol; 2011 Jun; 57(6):690-5. PubMed ID: 21394035
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of the HERG channel by droperidol depends on channel gating and involves the S6 residue F656.
Luo T; Luo A; Liu M; Liu X
Anesth Analg; 2008 Apr; 106(4):1161-70, table of contents. PubMed ID: 18349188
[TBL] [Abstract][Full Text] [Related]
25. 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels.
Gordon E; Lozinskaya IM; Lin Z; Semus SF; Blaney FE; Willette RN; Xu X
Mol Pharmacol; 2008 Mar; 73(3):639-51. PubMed ID: 18042732
[TBL] [Abstract][Full Text] [Related]
26. Effects of irbesartan on cloned potassium channels involved in human cardiac repolarization.
Moreno I; Caballero R; González T; Arias C; Valenzuela C; Iriepa I; Gálvez E; Tamargo J; Delpón E
J Pharmacol Exp Ther; 2003 Feb; 304(2):862-73. PubMed ID: 12538844
[TBL] [Abstract][Full Text] [Related]
27. Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities.
Marostica E; Van Ammel K; Teisman A; Boussery K; Van Bocxlaer J; De Ridder F; Gallacher D; Vermeulen A
J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):659-79. PubMed ID: 26259721
[TBL] [Abstract][Full Text] [Related]
28. Human ether-a-go-go-related (HERG) gene and ATP-sensitive potassium channels as targets for adverse drug effects.
Zünkler BJ
Pharmacol Ther; 2006 Oct; 112(1):12-37. PubMed ID: 16647758
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline.
Teschemacher AG; Seward EP; Hancox JC; Witchel HJ
Br J Pharmacol; 1999 Sep; 128(2):479-85. PubMed ID: 10510461
[TBL] [Abstract][Full Text] [Related]
30. State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy.
Ganapathi SB; Kester M; Elmslie KS
Am J Physiol Cell Physiol; 2009 Apr; 296(4):C701-10. PubMed ID: 19244476
[TBL] [Abstract][Full Text] [Related]
31. Molecular basis and drug sensitivity of the delayed rectifier (IKr) in the fish heart.
Hassinen M; Haverinen J; Vornanen M
Comp Biochem Physiol C Toxicol Pharmacol; 2015; 176-177():44-51. PubMed ID: 26215639
[TBL] [Abstract][Full Text] [Related]
32. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs.
Katchman AN; Koerner J; Tosaka T; Woosley RL; Ebert SN
J Pharmacol Exp Ther; 2006 Mar; 316(3):1098-106. PubMed ID: 16278312
[TBL] [Abstract][Full Text] [Related]
33. The hERG potassium channel and hERG screening for drug-induced torsades de pointes.
Hancox JC; McPate MJ; El Harchi A; Zhang YH
Pharmacol Ther; 2008 Aug; 119(2):118-32. PubMed ID: 18616963
[TBL] [Abstract][Full Text] [Related]
34. Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents.
Katchman AN; McGroary KA; Kilborn MJ; Kornick CA; Manfredi PL; Woosley RL; Ebert SN
J Pharmacol Exp Ther; 2002 Nov; 303(2):688-94. PubMed ID: 12388652
[TBL] [Abstract][Full Text] [Related]
35. Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide.
Milnes JT; Witchel HJ; Leaney JL; Leishman DJ; Hancox JC
J Pharmacol Toxicol Methods; 2010; 61(2):178-91. PubMed ID: 20172036
[TBL] [Abstract][Full Text] [Related]
36. Mallotoxin is a novel human ether-a-go-go-related gene (hERG) potassium channel activator.
Zeng H; Lozinskaya IM; Lin Z; Willette RN; Brooks DP; Xu X
J Pharmacol Exp Ther; 2006 Nov; 319(2):957-62. PubMed ID: 16928897
[TBL] [Abstract][Full Text] [Related]
37. Flunarizine is a highly potent inhibitor of cardiac hERG potassium current.
Trepakova ES; Dech SJ; Salata JJ
J Cardiovasc Pharmacol; 2006 Feb; 47(2):211-20. PubMed ID: 16495758
[TBL] [Abstract][Full Text] [Related]
38. Assessment of temperature-induced hERG channel blockade variation by drugs.
Kauthale RR; Dadarkar SS; Husain R; Karande VV; Gatne MM
J Appl Toxicol; 2015 Jul; 35(7):799-805. PubMed ID: 25348819
[TBL] [Abstract][Full Text] [Related]
39. Support vector machines classification of hERG liabilities based on atom types.
Jia L; Sun H
Bioorg Med Chem; 2008 Jun; 16(11):6252-60. PubMed ID: 18448342
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide.
Paul AA; Witchel HJ; Hancox JC
Biochem Biophys Res Commun; 2001 Feb; 280(5):1243-50. PubMed ID: 11162661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
